전신 마취제 시장 : 약제 분자별, 투여 경로별, 최종 사용자별, 지역별
General Anesthesia Drugs Market, By Drug molecule, By Route of Administration, By End User, By Geography
상품코드
:
1747534
리서치사
:
Coherent Market Insights
발행일
:
2025년 05월
페이지 정보
:
영문
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
전신 마취제 시장 규모는 2025년에 53억 6,000만 달러로 추정되고, 2032년에는 71억 달러에 이를 것으로 예측되며, 2025-2032년까지의 CAGR은 4.1%를 나타낼 전망입니다.
| 보고 범위 |
보고서 세부정보 |
| 기준 연도 |
2024년 |
시장 규모(2025년) |
53억 6,000만 달러 |
| 실적 데이터 |
2020-2024년 |
예측 기간 |
2025-2032년 |
| 예측 기간(2025-2032년) CAGR |
4.10% |
가치 예측(2032년) |
71억 달러 |
전신 마취제는 전신 마취에 사용되는 주요 약물 클래스 중 하나입니다. 질병, 심한 화상 및 외상성 뇌 손상 등 다양한 병리학에 대해 투여되지만 이에 국한되지는 않습니다.
시장 역학
마취제의 연구 개발 자금 증가는 예측 기간 동안 전신 마취제 시장 성장을 가속할 것으로 예측됩니다. 예를 들어, 2021년 8월 세인트루이스 워싱턴대학교 의과대학과 미시간대학교의 연구원들은 환자 중심 결과 연구소로부터 3300만 달러의 보조금을 받아 정맥 프로포폴과 흡입 마취제를 비교하여 일반적인 마취제 중 어떤 것이 환자의 회복 경험과 임상 결과를 개선하는 데 더 나은지 알아냈습니다.
제품 리콜은 예측 기간 동안 전신 마취제 시장 성장을 제한할 것으로 예측됩니다.
본 조사의 주요 특징
- 본 보고서에서는 전신 마취제 시장을 상세하게 분석하여 2024년을 기준연도로 한 예측기간 2025-2032년 시장 규모 및 복합연간 성장률(CAGR%)을 제공합니다.
- 다양한 부문에 걸친 잠재적인 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안의 매트릭스에 대해 해설했습니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품의 출시나 승인, 시장 동향, 지역별 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 중요한 인사이트도 제공합니다.
- 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등의 파라미터에 근거해, 세계의 전신 마취제 시장에 있어서 주요 기업 프로파일을 제공합니다.
- 이 보고서로부터의 인사이트는 마케팅 담당자나 기업의 경영진이, 향후 제품 발매, 유형 업그레이드, 시장 확대, 마케팅 전술에 관한 정보에 근거한 의사 결정을 실시하는 것을 가능하게 합니다.
- 이 조사 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등이 업계의 다양한 이해 관계자를 대상으로 합니다.
- 이해관계자는 세계의 전신 마취제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정이 용이해집니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 영향 분석
- 최근 개발
- 파이프라인 분석
- 유통 채널 분석
- 역학
- 합병, 인수 및 협업
- 규제 시나리오
- 주요 발전
- PEST 분석
제4장 세계의 전신 마취제 시장 : 약제 분자별(2020-2032년)
- 데스플루란
- 이소플루란
- 프로포폴
- 에토미 데이트
- 메토엑시탈
- 히오펜턴
- 미다졸람
- 케타민
제5장 세계의 전신 마취제 시장 : 투여 경로별(2020-2032년)
제6장 세계의 전신 마취제 시장 : 최종 사용자별(2020-2032년)
제7장 세계의 전신 마취제 시장 : 지역별(2020-2032년)
- 북미
- 유럽
- 영국
- 독일
- 이탈리아
- 프랑스
- 스페인
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- ASEAN
- 호주
- 한국
- 기타 아시아태평양
- 라틴아메리카
- 중동
- 아프리카
제8장 경쟁 구도
- 기업 프로파일
- Baxter Healthcare
- Reddy's Laboratories
- Novartis International AG
- Hospira
- Maruishi
- Hengrui
- Lunan
- Fresenius Kabi
- Pfizer Inc.
- Hikma Pharmaceuticals
- Sagent Pharmaceuticals
- Teva Pharmaceuticals
- Par Pharmaceutical
- Viatris Inc.
- AbbVie
- Piramal Critical Care
- Aspen Global Incorporated
- B. Braun SE
- Abbott
- Cosmo pharmaceuticals
제9장 섹션
KTH
영문 목차
General Anesthesia Drugs Market size is estimated to be valued at USD 5.36 Bn in 2025 and is expected to reach USD 7.1 Bn in 2032, exhibiting a compound annual growth rate (CAGR) of 4.1% from 2025 to 2032.
| Report Coverage |
Report Details |
| Base Year: |
2024 |
Market Size in 2025: |
USD 5.36 Bn |
| Historical Data for: |
2020 To 2024 |
Forecast Period: |
2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: |
4.10% |
2032 Value Projection: |
USD 7.1 Bn |
General anesthetics is one of the major classes of drugs used for general anesthesia. General anesthetics can be administered for a number of medical conditions including but not limited to the following: respiratory problems, such as lung cancer and asthma; cardiac problems, such as congenital heart disease and myocardial infarction; neurological disorders, such as seizures and Parkinson's disease; severe burns and traumatic brain injury. General anesthesia can also be given for cosmetic reasons, such as breast augmentation and nose surgery.
Market Dynamics
Increasing funding for R&D in anesthetic drugs is expected to propel growth of the general anesthesia drugs market over the forecast period. For instance, in August 2021, researchers at Washington University School of Medicine in St. Louis and the University of Michigan received a US$ 33 million grant from the Patient-Centered Outcomes Research Institute to compare intravenous propofol to inhaled anesthetic drugs to determine which of the common anesthetic drugs offers better patient recovery experiences and improved clinical outcomes.
Product recall is expected to limit growth of the general anesthesia drugs market over the forecast period. For instance, in May 2021, Hospira announced to recall one lot each of the injectable hospital anesthetics bupivacaine HCL and lidocaine HCL due to mislabeling of product.
Key features of the study
- This report provides in-depth analysis of the general anesthesia drugs market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global general anesthesia drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Baxter International Inc., AstraZeneca, AbbVie Inc., B. Braun Melsungen AG, Fresenius SE & Co. KGaA, and Hospira Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global general anesthesia drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global general anesthesia drugs market
Detailed Segmentation
- Global General Anesthesia Drugs Market, By Molecule Type
- Propofol
- Sevoflurane
- Dexmedetomidine
- Desflurane
- Remifentanil
- Midazolam
- Global General Anesthesia Drugs Market, By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Baxter Healthcare
- Dr. Reddy's Laboratories
- Fresenius KabiPfizer Inc.
- Hikma Pharmaceuticals
- Sagent Pharmaceuticals
- Teva Pharmaceuticals
- Par Pharmaceutical
- Viatris Inc.
- AbbVie
- Piramal Critical Care
- Aspen Global Incorporated
- B. Braun SE
- Abbott
- COSMO PHARMACEUTICALS
- Hospira Inc.
- Maruishi
- Hengrui
- Lunan
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Molecule
- Market Snippet, By Route of Administration
- Market Snippet, By End User
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Development
- Pipeline Analysis
- Distribution Channel Analysis
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global General Anesthesia Drug Market , By Drug Molecule, 2020 - 2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
- Desflurane
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Segment Trends
- Isoflurane
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Segment Trends
- Propofol
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Segment Trends
- Etomidate
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Segment Trends
- Methoexital
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Segment Trends
- Hiopentone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Segment Trends
- Midazolam
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Segment Trends
- Ketamine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Segment Trends
5. Global General Anesthesia Drug Market , By Route of Administration, 2020 - 2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
- Intravenous Anesthesia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Segment Trends
- Inhalation Anesthesia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Segment Trends
6. Global General Anesthesia Drug Market , By End User, 2020 - 2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
- Hospital
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
7. Global General Anesthesia Drug Market , By Region, 2020 - 2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
- North America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Molecule, 2020 -2032, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2020 -2032, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 - 2032, (US$ Bn)
- Europe
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Molecule, 2020 -2032, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2020 - 2032, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 - 2032, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Molecule, 2020 -2032, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2020 - 2032, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 - 2032, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Molecule, 2020 -2032, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2020 - 2032, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 - 2032, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Molecule, 2020 -2032, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2020 - 2032, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 - 2032, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Molecule, 2020 -2032, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2020 - 2032, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 - 2032, (US$ Bn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Company Profiles
- Baxter Healthcare
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Reddy's Laboratories
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Novartis International AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Hospira
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Maruishi
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Hengrui
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Lunan
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Fresenius Kabi
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Hikma Pharmaceuticals
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Sagent Pharmaceuticals
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Teva Pharmaceuticals
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Par Pharmaceutical
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Viatris Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- AbbVie
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Piramal Critical Care
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Aspen Global Incorporated
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- B. Braun SE
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Abbott
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Cosmo pharmaceuticals
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
9. Section
- References
- Research Methodology
- About us and Sales Contact
관련자료
